Targeting DPY30 selectively inhibited tumor formation in vivo without impairing GSC proliferation in vitro, suggesting its role in reprogramming the H3K4me3 landscape to support angiogenesis and hypoxia-related signaling in the tumor microenvironment (TME). The gene discussed is DPY30; the disease is neoplasm.